If you are experiencing problems downloading PDF or HTML fulltext, our helpdesk recommend clearing your browser cache and trying again. If you need help in clearing your cache, please click here . Still need help? Email help@ingentaconnect.com

Immunotherapy with Peptides in Systemic Lupus Erythematosus

$63.10 plus tax (Refund Policy)

Buy Article:

Abstract:

In systemic lupus erythematosus (SLE), the interaction between hyperactive T cells and B cells causes a dysregulated production of autoantibodies that can lead to tissue damage and impaired organ function. Studies on the modalities of communication between T and B cells have led to the design of new therapeutics for SLE, including autoantibodyderived peptide immunotherapies. Since many autoantibodies in SLE patients have amino acid sequences similar to those of murine antibodies, and at similar locations, the current directions are to employ strategies that have given promising results in mice in human clinical settings. This review describes the experimental evidence, rationale, and preclinical models of autoantibody-derived peptide immunotherapy in SLE, and how this information is translating into clinical studies in humans.

Document Type: Research Article

DOI: http://dx.doi.org/10.2174/092986709787909659

Affiliations: Department of Medicine, David Geffen School of Medicine at the University of California Los Angeles, Los Angeles, California 90095-1670, USA.

Publication date: April 1, 2009

More about this publication?
  • Current Medicinal Chemistry covers all the latest and outstanding developments in medicinal chemistry and rational drug design. Each issue contains a series of timely in-depth reviews written by leaders in the field covering a range of the current topics in medicinal chemistry. Current Medicinal Chemistry is an essential journal for every medicinal chemist who wishes to be kept informed and up-to-date with the latest and most important developments.
Related content

Tools

Favourites

Share Content

Access Key

Free Content
Free content
New Content
New content
Open Access Content
Open access content
Subscribed Content
Subscribed content
Free Trial Content
Free trial content
Cookie Policy
X
Cookie Policy
ingentaconnect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more